» Authors » Naresh Bumma

Naresh Bumma

Explore the profile of Naresh Bumma including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 45
Citations 485
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Richter J, Dhodapkar M, Li M, Awad M, Hampp C, Knorr K, et al.
Am J Hematol . 2025 Jan; 100(4):548-551. PMID: 39887567
No abstract available.
2.
Bhatt K, Delgado D, Khella S, Bumma N, Karam C, Keller A, et al.
J Am Heart Assoc . 2024 Nov; 13(23):e033770. PMID: 39575713
Background: Diagnosis of hereditary amyloid transthyretin (hATTR) amyloidosis with cardiomyopathy is frequently delayed, in large part because of symptom overlap with other cardiovascular diseases and limited provider knowledge of this...
3.
Voorhees P, Sborov D, Laubach J, Kaufman J, Reeves B, Rodriguez C, et al.
Future Oncol . 2024 Oct; 21(1):25-49. PMID: 39452950
No abstract available.
4.
Chari A, Kaufman J, Laubach J, Sborov D, Reeves B, Rodriguez C, et al.
Blood Cancer J . 2024 Jul; 14(1):107. PMID: 38977707
The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up, 49.6 months) of...
5.
Bumma N, Richter J, Jagannath S, Lee H, Hoffman J, Suvannasankha A, et al.
J Clin Oncol . 2024 Jun; 42(22):2702-2712. PMID: 38879802
Purpose: We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody...
6.
Callander N, Silbermann R, Kaufman J, Godby K, Laubach J, Schmidt T, et al.
Blood Cancer J . 2024 Apr; 14(1):69. PMID: 38649340
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present...
7.
Silbermann R, Laubach J, Kaufman J, Sborov D, Reeves B, Rodriguez C, et al.
Am J Hematol . 2024 Apr; 99(7):1257-1268. PMID: 38622840
In the phase 2 GRIFFIN trial (ClinicalTrials.gov identifier: NCT02874742), daratumumab added to lenalidomide, bortezomib, and dexamethasone (D-RVd) improved depth of response and progression-free survival (PFS) versus lenalidomide, bortezomib, and dexamethasone...
8.
Waidyaratne G, Bennett C, Umyarova E, Bumma N
J Hematol . 2024 Jan; 12(6):283-286. PMID: 38188473
Cement emboli are a well-established complication of kyphoplasties and vertebroplasties and can easily be mistaken for wires. While kyphoplasties are commonly performed for vertebral fractures caused by metastases from malignancies...
9.
Stino A, Bumma N, Smith R, Davalos L, Allen J, Ye J, et al.
Eur J Neurol . 2023 Nov; 31(3):e16164. PMID: 38015467
Background: Anti-myelin-associated glycoprotein (MAG) neuropathy is a debilitating demyelinating polyneuropathy with no approved therapies. Our primary objective was to ascertain lenalidomide safety and maximum tolerated dose (MTD) in anti-MAG neuropathy....
10.
Campbell C, Baiyee C, Almaani S, Bumma N, Sharma N, LoRusso S, et al.
Am J Ther . 2023 Sep; 30(5):e447-e453. PMID: 37713689
Background: Deposition of wild-type or mutant transthyretin (TTR) amyloid fibrils in the myocardium causes TTR amyloid cardiomyopathy (ATTR-CM). Targeted therapeutics for ATTR-CM include TTR stabilizers (tafamidis and diflunisal) and oligonucleotide...